(0.06%) 5 472.56 points
(0.10%) 39 150 points
(0.34%) 17 779 points
(-0.22%) $80.65
(-3.66%) $2.66
(-0.78%) $2 312.60
(0.21%) $28.93
(3.50%) $1 020.90
(0.28%) $0.936
(0.70%) $10.68
(0.45%) $0.792
(-0.28%) $87.25
Live Chart Being Loaded With Signals
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States...
Stats | |
---|---|
今日成交量 | 364 324 |
平均成交量 | 694 746 |
市值 | 130.93M |
EPS | $-0.290 ( Q1 | 2024-05-09 ) |
下一个收益日期 | ( $0 ) 2024-08-06 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-1.380 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00200 (0.10%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-20 | Rastetter William H | Buy | 60 000 | Stock Option (Right to Buy) |
2024-05-20 | Papadopoulos Stelios | Buy | 60 000 | Stock Option (Right to Buy) |
2024-05-20 | Witz Pascale | Buy | 60 000 | Stock Option (Right to Buy) |
2024-05-20 | Rosen Hugh | Buy | 60 000 | Stock Option (Right to Buy) |
2024-05-20 | Nunn Jason Raleigh | Buy | 60 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
99.26 |
Last 99 transactions |
Buy: 15 333 605 | Sell: 34 706 |
音量 相关性
Regulus Therapeutics Inc 相关性 - 货币/商品
Regulus Therapeutics Inc 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $-227 000 (0.00 %) |
EPS: | $-1.580 |
FY | 2023 |
营收: | $0 |
毛利润: | $-227 000 (0.00 %) |
EPS: | $-1.580 |
FY | 2022 |
营收: | $0 |
毛利润: | $-122 000 (0.00 %) |
EPS: | $-1.860 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-3.19 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Regulus Therapeutics Inc
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。